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ABSTRACT 
BACKGROUND:  Vascular and inflammatory processes have been reported to be factors 
in the pathogenesis of diabetic neuropathy. Angiopoietin-1 (Angl) plays essential roles in 
regulating vascular growth, development, maturation, permeability, and inflammation. 
OBJECT IVE:  The aim of this study was to investigate the effect of cartilage oligo- 
meric matrix protein (COMP)-Angl, which is a soluble, stable, potent Angl variant, on 
peripheral nerves in db/db diabetic mice. 
METHODS:  The db/db diabetic mice were randomized into 2 groups based on 
their weight and glucose level and treated with recombinant adenovirus (Ade), express- 
ing either COMP-Angl or the ~-galactosidase g ne (LacZ) (control), for 8 weeks. 
Immunohistochemistry was performed using a polyclonal ntibody of antiprotein gene 
product and a secondary antibody. Intraepidermal nerve fiber density (IENFD) was quan- 
tified as nerve fiber abundance per unit length of epidermis (IENF/mm). In addition, the 
total capillary length (TCD per unit length of epidermis was summed (mm/mm2). All 
slides were coded and the capillary length and the number of nerve fibers were calcu- 
lated by a blinded observer. 
RESULTS:  Ten diabetic db/db mice (mean [SD] weight, 38.7 [1.95] g) were random- 
ized to receive Ade-COMP-Angl or Ade-LacZ. IENFD was significantly greater in the 
Ade-COMP-Angl group compared with the Ade-LacZ group (mean [SD] 8.95 [3.30] vs 
3.57 [0.73]/mm; P < 0.05). TCL was also significantly greater in the Ade-COMP-Angl 
group (2.79 [0.99] vs 2.04 [0.58] mm/mm2; P < 0.05). Compared with baseline, fasting 
blood glucose concentration fter8 weeks of treatment decreased significantly more in 
the Ade-COMP-Angl group than in the Ade-LacZ group (489 [45] to 361 [81] vs 495 
[48] to 521 [70] mg/dL; P < 0.05). 
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CONCLUSIONS:  These results suggest hat Ade-COMP-Angl might have had 
proliferative ffects on peripheral nerve and cutaneous capillaries in this small animal 
study. Further investigation of the metabolic effect, target site, and related mediator of 
COMP-Angl is needed. (Curr Ther Res C/in Exp, 2008;69:343 55) © 2008 Excerpta 
Medica Inc. 
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INTRODUCTION 
Despite the fact that peripheral neuropathy is a serious microvascular complication and 
a leading cause of foot amputation, which increases the mortality rate of diabetic 
patients, many study outcomes attempting to clarify pathogenic mechanisms or to suc- 
cessfully treat diabetic neuropathy have been unsatisfactory) Because hyperglycemia is 
a major factor in the development ofdiabetic neuropathy, strict control of blood glucose 
concentration is an essential strategy in the prevention and treatment of this condi- 
tion. 2,3 Inflammation is increased in diabetes, and enhanced inflammatory response can 
cause nerve injury in experimental neuropathy. 4 In addition, neural cell degeneration 
and decreased nerve blood flow have been reported to be pathophysiologic features of 
diabetic neuropathy. 5 Treatment with growth factors and anti-inflammatory agents that 
prevent neural cell degeneration and improve blood flow directly or indirectly might be 
considered an effective therapeutic approach. 
In addition to promoting angiogenesis, angiopoietin-1 (Angl) is known to stabilize 
endothelium and to have anti-inflammatory effects6; however, it is unclear whether 
Angl also has a beneficial effect on peripheral nerve growth related to cutaneous vascu- 
lature in the diabetic animal model. Cartilage oligomeric matrix protein (COMP)-Angl 
is an Angl variant hat is reported to be a more effective therapeutic agent han native 
Angl in the way of efficiency, generation, and potency. 7,8 For systemic treatment with 
COMP-Angl, 2 adenoviral vectors were developed that encode the COMP-Angl gene 
and the ~-galactosidase gene (LacZ). By delivering adenovirus (Ade)-COMP-Angl using 
a viral vector, long-term, sustained COMP-Angl circulation can be maintained. 9 
This study investigated the neuroprotective effect of Ade-COMP-Angl, a soluble, 
stable, potent Angl variant, by estimating intraepidermal nerve fiber density (IENFD) 
and cutaneous vascularity in db/db diabetic mice. 
MATERIALS  AND METHODS 
COMP-ANG1 AND ADE-COMP-ANG1 PREPARATION 
Ade-COMP-Angl was made from recombinant Chinese hamster ovary ceils. A re- 
combinant adenovirus that could express COMP-Angl or LacZ was constructed using 
the pAdEasy vector system (Qbiogene, Inc., Irvine, California), as was done in previous 
studies .7,8 
ANIMALS 
Male rib/rib mice were purchased from Jackson Laboratories (Bar Harbor, Maine) and 
housed in our pathogen-free animal facility; 8- to 10-week-old mice were used for this 
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study. The animal care protocol and the xperimental procedures were approved by the 
Institutional Animal Care and Use Committee of the Chonbuk National University 
Medical School (Jeonju, South Korea). 
STUDY DES IGN 
For this study, rib/rib mice that were similar in weight and blood glucose con- 
centration were randomized based on weight and glucose level into 2 groups, and 
109 plaque-forming units of Ade-COMP-Angl or Ade-LacZ diluted in 50 laL of sterile 
0.9% sodium chloride was injected intravenously through the tail vein for adenoviral 
treatment. Serum concentrations of Ade-COMP-Angl remained at elevated concentra- 
tions for 2 weeks, as previously described. 1°Consequently, Ade-COMP-Angl or Ade- 
LacZ was injected 4 times at 2-week intervals. In a preliminary study, we found that 
LacZ had no effect on weight, blood glucose concentration, or other measured param- 
eters in the same animal model. Therefore, LacZ was used as the control agent. 
Weight, blood glucose concentration, and food intake were measured at baseline 
and at 2-week intervals. Blood glucose concentration was measured in a sample drawn 
from a tail vein using Precision Xtra Plus ® (Abbott Laboratories, MediSense Products, 
Bedford, Massachusetts), and serum insulin concentration was analyzed using a radio- 
immunoassay (Neodine Laboratories, Seoul, South Korea). After 8 weeks of treatment, 
the mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and a 
punch biopsy of skin 3 mm in diameter was performed on the dorsum of both feet to 
quantify the degree of innervation and vascularity. 
IMMUNOHISTOCHEMISTRY 
For immunohistochemistry on frozen microtome sections, skin tissue specimens 
were fixed with periodate-lysine-paraformaldehyde (2 % paraformaldehyde, 0.075 M lysine, 
0.05 M phosphate buffer pH 7.4, 0.01 M sodium m-periodate) solution for 24 hours. 
After thorough rinsing in phosphate-buffered saline (PBS), which contained 20% glycerol 
and 0.1 M phosphate buffer, for 48 hours at 4°C, tissue specimens underwent cryo- 
protection with Tissue-Tec ® (OCT compound) (Miles, Elkhart, Indiana). Sections 
40 lam were cut on a sliding microtome (Leica CM 1510 ®, Leica Microsystems AG, 
Wetzlar, Germany) perpendicular to the dermis and were immerged in PBS for 
15 minutes at room temperature. Samples were then transferred into microtubules 
containing Dako Protein Block Serum-Free ® (Dako Corporation, Carpinteria, 
California) as a blocking buffer supplemented with 3% goat serum. After 30 minutes 
in the blocking buffer on a shaker table at room temperature, sectioned specimens 
were washed with PBS twice for 10 minutes and then incubated separately overnight 
at 4°C in 1 of 2 primary antibodies rabbit antiprotein-gene-product 9.5 (PGP 9.5) 
(Biogenesis, Poole, United Kingdom) for peripheral nerves at a dilution of 1:100 or 
hamster antimouse CD31 (1:100) (Chemicon International Inc., Temecula, California) 
for capillary endothelial ceils. The antibodies were diluted in antibody diluent (Dako 
Corporation) supplemented with 1% goat serum. After a sterile washing, the relevant 
secondary ant ibod ies~oat  ntirabbit immunoglobulin G (IgG)-FITC (1:200) or Cy3 
Aff]niPure goat antiarmenian hamster IgG (heavy and light chain) (1:200) (Jackson 
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ImmunoResearch Laboratories Inc., West Grove, Pennsylvania) were separately 
loaded (ie, immunostained) for 1 hour at room temperature in a dark room. After 
washing with PBS as above, sections were placed on slides and prepared with fluores- 
cent mounting medium (Dako Corporation). 
QUANTIF ICAT ION OF  INNERVATION AND CAP ILLARY VASCULARITY  
PGP 9.5 immunoreactive n rve fibers in the epidermis of each section were counted 
at a magnification of 100x. Each individual nerve fiber with branching points inside 
the epidermis was counted as 1 fiber. For epidermal nerve fibers with branching points 
inside the dermis, each individual nerve fiber was counted separately. Conventional 
IENFD was derived and expressed as epidermal nerve fiber abundance per unit length 
of the epidermis (IENFD/mm). IENFD was calculated by a blinded observer, and all 
biopsy slides were coded and mixed with a set of normal slides to ensure examiner 
blinding. Photomicrographs of representative s ctions were captured using a digital 
camera (Axiocam HRC ®, Carl Zeiss, Goettingen, Germany). 
Capillary vascularity was also observed (by a blinded investigator) using the same 
method that was used to determine IENFD, including the photomicrographs. Images 
were collected and analyzed using a microscope (Axioskop2, Carl Zeiss Ltd., Welwyn 
City, United Kingdom) and the Axiovision 5.1 program (Carl Zeiss Ltd.). 
STAT IST ICAL  ANALYS IS  
A power analysis (90%) was performed to determine sample size. Based on the 
power analysis, 5 mice per group were needed to detect significant between-group 
differences. 
Data were presented as mean (SD). The unpaired t test was used to compare the Ade- 
LacZ and Ade-COMP-Angl groups. P < 0.05 was considered statistically significant. 
All statistical analyses were performed using SPSS 12.0 software (SPSS Inc., Chicago, 
Illinois). 
RESULTS 
ANIMALS 
Five mice (mean [SD] weight, 38.7 [1.95] g) were assigned to each of the 2 groups. 
EFFECTS OF  ADE-COMP-ANG1 ON CHARACTERIST ICS  OF  dbldb MICE 
Characteristics of db/db mice after IV administration of Ade-LacZ or Ade-COMP- 
Angl for 8 weeks (4 injections at 2-week intervals) are presented in Table I. Before 
treatment (baseline), the mice in the 2 groups did not differ significantly in age (data 
not shown), weight, food intake, or fasting blood glucose concentration. Although there 
was no significant difference in food intake between the groups during the experimen- 
tal period, both body weight (51.8 [1.7] vs 54.1 [2.2] g; P < 0.05) and fasting blood 
glucose concentration (361 [81] vs 521 [70] mg/dL; P < 0.05) were significantly lower in 
the Ade-COMP-Angl group compared with the Ade-LacZ group. However, there was 
no significant between-group difference in serum insulin concentration after treatment 
(39.5 [5.1] vs 39.7 [3.9] laU/mL) (Table I). 
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Table I. Characteristics of the diabetic db/db mice at baseline and after 8 weeks of treat- 
ment (N = 10).  Data are mean (SD). 
Ade-COM P-Angl Ade-LacZ 
(n = 5) (n = 5) 
Characteristic Baseline Week 8 Baseline Week 8 
Weight, g 
Food intake, g/24 h 
Serum insulin, pU/mL 
Fasting blood glucose, mg/dL 
IENFD, no./mm 
Total capillary length per unit 
length of epidermis, mm/mm 2 
38.6 (2.1) 51.8 (1.7)* 38.8 (1.9) 54.1 (2.2) 
7.8 (1.1) 8.3 (0.5) 7.8 (0.8) 8.2 (0.7) 
39.5 (5.1) 39.7 (3.9) 
489 (45) 361 (81)* 495 (48) 521 (70) 
8.95 (3.30)* 3.57 (0.73) 
2.79 (0.99)* 2.04 (0.58) 
Ade = adenovirus; COMP = cartilage oligomeric matrix protein; Angl = angiopoietin-1; 
~-galactosidase gene; IENFD = intraepidermal nerve fiber density. 
*P < 0.05 versus Ade-LacZ-treated group. 
LacZ : 
EFFECTS OF ADE-COMP-ANG1 ON INTRAEP IDERMAL NERVE F IBERS 
Mean (SD) IENFD was significantly greater (>2-fold) in the Ade-COMP-Angl group 
compared with the Ade-LacZ group (8.95 [3.30] vs 3.57 [0.73]/mm; P < 0.05). IENFD 
of each mouse is shown in Table II. The morphologic findings of lENFD in each group 
appeared to increase (Figure 1). 
EFFECTS OF ADE-COMP-ANG1 ON TOTAL CAP ILLARY LENGTH 
Mean (SD) total capillary length (TCL) was also significantly greater in the Ade- 
COMP-Angl group than in the Ade-LacZ group (2.79 [0.99] vs 2.04 [058] ram/ram2; 
P < 0.05). TCL for each mouse is shown in Table II; the increased pattern ofvascularity 
Table II. Intraepidermal nerve fiber density (IENFD) and total capillary length (TCL) of 
the individual diabetic db/db mice after 8 weeks of t reatment with adenovi- 
rus (Ade)-carti lage oligomeric matrix protein-angiopoietin-1 (COMP-Ang l )  or 
Ade-~-galactos idase gene (LacZ). Data are mean (SD). 
Ade-COM P-Angl-Treated Ade-LacZ-Treated 
IENFD TCL IENFD TCL 
Mouse 1 6.18 (1.23) 3.33 (0.72) 3.22 (0.74) 2.36 (0.59) 
Mouse 2 12.52 (6.37) 2.72 (0.57) 4.88 (1.74) 1.83 (0.62) 
Mouse 3 8.98 (3.71) 2.88 (0.71) 3.32 (2.17) 2.07 (0.54) 
Mouse 4 7.32 (2.36) 2.18 (0.38) 3.17 (0.63) 1.95 (0.56) 
Mouse 5 9.76 (4.94) 2.85 (2.61) 3.29 (1.22) 2.01 (0.61) 
Mean (SD) 8.95 (3.30) 2.79 (0.99) 3.57 (0.73)* 2.04 (0.58) 
*P < 0.05 versus Ade-COMP-Angl-treated group. 
347 
CURRENT THERAPEUTIC  RESEARCH 
Figure 1. Intraepidermal nerve fiber density (IENFD) in db/db diabetic mice after 
8 weeks of treatment with (A) adenovirus (Ade)-carUlage oligomeric matrix 
protein-angiopoietin-1 (COMP-Angl) or (B) Ade-~-galactosidase gene (LacZ). 
Arrows indicate the peripheral nerves maintained in the epidermis, which was 
branched in the dermis (200X); capillary endothelial immunostaining with 
hamster antimouse CD31. 
(continued) 
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in the Ade-COMP-Angl group is presented in schematic fashion in Figure 2 (includ- 
ing photomicrographs). 
DISCUSSION 
Diabetic neuropathy is one of the most important factors affecting the prognosis of 
diabetic patients. Approximately half of diabetic patients are reported to have neuro- 
pathic symptoms. 11 In particular, significant morbidity among diabetic patients is 
associated with sensory deficit of the lower extremities, potentially resulting in foot 
ulceration or amputation. Prevention and treatment of diabetic neuropathy have often 
been unsatisfactory. The effects of various agents on a hypothesized pathogenic cause of 
B 
\ 
Figure 2. Cutaneous capillary vascularity shown in schematic representations of 
skeletonized microvessels of db/db diabetic mice after 8 weeks of treatment 
with (A) adenovrius (Ade)-cartilage oligomeric matrix protein-angiopoieUn-1 
(COMP-Angl) and (B) Ade-13-galactosidase gene (LacZ) (200X; capillary 
endothelial immunostaining with hamster antimouse CD31). 
(continued) 
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diabetic neuropathy have been investigated in both experimental nd clinical trials. 
Most of these agents have been found to have promising results in experimental studies, 
but the findings in clinical trials have been less convincing. 12,13 
Several factors, including hyperglycemia, the polyol pathway, protein kinase C (PKC), 
and nonenzymatic glycation have been postulated to be involved in the pathogenesis 
of diabetic neuropathy. 14 16 Most therapeutic agents for the treatment of diabetic neu- 
ropathy have been focused on these putative mechanisms. 17 21 Reports suggest that 
vascular factors, including microangiopathy or endoneural ischemia, and neuropathic 
processes may be associated with diabetic neuropathy. 2°,22 In addition, studies have 
found that increased inflammation i diabetes can cause peripheral nerve injury. 4New 
anti-inflammatory strategies targeting both the neurotrophic and angiogenic aspects of 
diabetic neuropathy may be possible therapies. 
Angl is a ligand of the Tie2 receptor, which is a member of the tyrosine kinase fami- 
ly that is expressed on vascular endothelial ceils. Angl, which is mediated by phospho- 
rylating the Tie2 receptor and signaling via the Akt pathway, has therapeutic potential 
in angiogenesis and vascular endothelial dysfunction; however, Angl has aggregation 
and insolubility problems due to the superclustering domain and multimerization of
Angl. 23 For these reasons, a chimeric form of Angl with COMP (COMP-Angl) was 
developed to avoid these limitations. COMP-Angl is a soluble, stable, potent Angl 
variant hat has been found to be effective in preventing endothelial dysfunction and 
inflammation. 7,8However, the effect of COMP-Angl on peripheral neuropathy in dia- 
betes has not yet been studied in experimental models. Therefore, we investigated the 
effects of COMP-Angl on peripheral nerves of,rib/rib diabetic mice. 
Inflammatory mediators have been reported to be pathogenic mechanisms of 
diabetic neuropathy. 24,25 We reported that the anti-inflammatory effect of COMP- 
Angl involves inhibiting the nuclear factor (NF)-KB pathway, which subsequently 
decreases activation of transforming rowth factor (TGF)-~. 1° We also reported that 
COMP-Angl could increase blood flow by improving endothelial survival and vascular 
size. 26'27 Vascular factors related to tissue blood flow that can be targeted for treatment 
in diabetic peripheral neuropathy include increasing endothelium-derived relaxing 
factor, inhibition of PKC, suppression of NF-KB, and modulation of vascular endothe- 
lial growth factor (VEGF) subtype. Several factors that have an angiogenic effect (eg, 
VEGF, hepatocyte growth factor, fibroblast growth factor) have been reported to have 
therapeutic potential in diabetic neuropathy. 28 30 Neurotrophic factors, such as nerve 
growth factor, have been studied in animal models of diabetic neuropathyS; however, 
the clinical usefulness of this therapy was limited by the absence of an established 
therapeutic dose and reliable data. 
In this study, the effect of COMP-Angl might not have been mediated by direct 
action on peripheral nerves; rather, COMP-Angl may have triggered the activation of a 
cytokine cascade involved in nerve regeneration or inhibition of nerve degeneration i  
association with angiogenesis. Although previous studies have identified the effect of 
COMP-Angl on cytokines, a variety of cytokines will need to be investigated (includ- 
ing histologic analysis) to clarify the mechanism of action of COMP-Angl in angiogene- 
sis and nerve regeneration i  diabetic neuropathy. 8 10 
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In this study, fasting blood glucose concentration was significantly lower in db/db 
mice treated with Ade-COMP-Angl compared with those treated with Ade-LacZ. 
However, the serum insulin concentration was not significantly difterent between the 
2 groups. These results suggest hat the insulin-sensitizing eftect and resulting meta- 
bolic eftects of COMP-Angl might also contribute to neuroprotection in diabetic mice. 
Therefore, the metabolic eftect of COMP-Angl in diabetic mice, including its exact 
mechanism of action, and another group showing similar glucose control with COMP- 
Angl warrant further investigation. 
In our study, IENFD and TCL were greater in the group treated with Ade-COMP- 
Angl compared with the Ade-LacZ group. An increased number of nerve fibers and 
enriched vascularity were observed in the series of photomicrographs in the Ade- 
COMP-Angl group. 
L IMITAT IONS 
Our study had several limitations. The effects of COMP-Angl on peripheral nerves 
and capillaries might be related to its glucose-lowering effects. Next, if IENFD and 
TCL in both groups were measured prior to treatment and compared with our findings 
after treatment, it would have been more evident whether COMP-Angl indeed had a 
proliferative ffect on diabetic peripheral neuropathy. Therefore, we cannot definitively 
conclude that COMP-Angl protected the mice from any subtle loss of nerve fibers or 
vascularity or that it was associated with improvement in these factors when compared 
with LacZ. Finally, the presence of COMP-Angl receptors in the peripheral nerves and 
the related mediators uch as TGF-~ or NF-KB, were not investigated in this study 
(except o observe the morphologic changes), which would reveal more precise vidence 
on COMP-Angl effects. 
CONCLUSIONS 
These db/db diabetic mice treated with Ade-COMP-Angl had greater IENFD and cuta- 
neous capillary length compared with the Ade-LacZ group in this small animal study. 
We suggest hat Ade-COMP-Angl might have therapeutic potential, with a dual 
impact on peripheral nerves and cutaneous capillaries in this diabetic animal model. 
Ade-COMP-Angl treatment might also improve blood glucose concentration. Further 
studies targeting molecular markers and COMP-Angl receptors in peripheral nerves are 
warranted to determine the direct eftect of COMP-Angl on neural ceils. 
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